Parametric Portfolio Associates’s Apellis Pharmaceuticals APLS Stock Holding History

Parametric Portfolio Associates’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.64M	Sell	32,298 -11,435	-26%	-$505K	﹤0.01%	2526
2021 Q4	$2.07M	Sell	43,733 -6,157	-12%	-$242K	﹤0.01%	2418
2021 Q3	$1.64M	Sell	49,890 -7,858	-14%	-$442K	﹤0.01%	2542
2021 Q2	$3.65M	Buy	57,748 +26,858	+87%	+$1.39M	﹤0.01%	2068
2021 Q1	$1.32M	Sell	30,890 -21,903	-41%	-$1.04M	﹤0.01%	3027
2020 Q4	$3.02M	Buy	52,793 +31,167	+144%	+$1.32M	﹤0.01%	2399
2020 Q3	$652K	Sell	21,626 -9,178	-30%	-$274K	﹤0.01%	3138
2020 Q2	$1.01M	Buy	30,804 +20,854	+210%	+$670K	﹤0.01%	2918
2020 Q1	$267K	Buy	9,950 +409	+4%	+$14.5K	﹤0.01%	3435
2019 Q4	$292K	Sell	9,541 -759	-7%	-$21K	﹤0.01%	3575
2019 Q3	$248K	Buy	+10,300	New	+$283K	﹤0.01%	3626

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parametric Portfolio Associates's APLS Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Apellis Pharmaceuticals (APLS) stake by 26% in Q1 2022, selling an estimated $505K and leaving 32,298 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2526.

Parametric Portfolio Associates first reported a position in APLS in Q3 2019 and has held it in 11 quarters since. The position peaked at $3.65M in Q2 2021. 212 funds tracked by Wall St. Rank hold APLS as of Q1 2022.

Parametric Portfolio Associates held 32,298 shares of Apellis Pharmaceuticals worth $1.64M as of Q1 2022.
Parametric Portfolio Associates sold 11,435 Apellis Pharmaceuticals shares in Q1 2022, an estimated $505K.
Apellis Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2526 holding.
Parametric Portfolio Associates first reported a position in Apellis Pharmaceuticals in Q3 2019 and has held it in 11 quarters since.
Parametric Portfolio Associates's Apellis Pharmaceuticals position peaked at $3.65M in Q2 2021.
212 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.